Evaluation of One‐Time Oral Oclacitinib Administration on Pruritic Behaviours After Intradermal Interleukin‐31‐Induced Pruritus Injections (“Reactive” Model) in Healthy Dogs: A Blinded, Randomised, Cross‐Over Study
Veterinary Dermatology · 2025
DOI: 10.1111/vde.70010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2025. Verfasst von Renato Leon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA. Hauptthemen laut MEDLINE: Pyrimidines, Pruritus, Dog Diseases, Sulfonamides. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Administration of interleukin (IL)‐31 to healthy dogs has been used in preclinical drug testing to evaluate the antipruritic effect of novel medications through a “preventative” design approach (i.e., drugs are given before IL‐31 administration). Hypothesis/Objectives Develop and validate a “reactive” intradermal IL‐31‐induced pruritus model in healthy dogs by administering oral oclacitinib. Animals Eight adult, healthy research‐bred beagles. Materials and Methods A blinded, randomised, cross‐over study. All dogs received either intradermal recombinant canine IL‐31 with or without a single dose of oral oclacitinib given afterward; cross‐over treatment was administered following a 4‐week washout period.
Results
Oclacitinib reduced the total ( p = 0.0252) and local ( p = 0.0078) pruritic behaviour seconds after intradermal IL‐31 injections. It also reduced the total seconds of scratching ( p = 0.0078), chewing/biting ( p = 0.0078) and head‐shaking ( p = 0.0255) behaviours. No significant reduction in licking was observed. Decreases in total pruritic seconds in this “reactive” model following oclacitinib administration were observed at 120–180 min ( p = 0.0058), 180–240 min ( p = 0.0075) and 240–300 min ( p = 0.0241). Likewise, decreases in local pruritic behaviour seconds were observed at 60–120 min ( p = 0.0498) and 240–300 min ( p = 0.0343). Conclusions and Clinical Relevance The study established the first “reactive” canine intradermal IL‐31 itch model in healthy dogs. One‐time oral administration of oclacitinib significantly reduced the incidence of pruritic behaviours. Novel antipruritic medications can be assessed and compared using this “reactive” model in future preclinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
ORCID-Profile: Renato Leon, Frane Banovic
Zitieren
APA
Leon, R., Starr, H., & Banovic, F. (2025). Evaluation of One‐Time Oral Oclacitinib Administration on Pruritic Behaviours After Intradermal Interleukin‐31‐Induced Pruritus Injections (“Reactive” Model) in Healthy Dogs: A Blinded, Randomised, Cross‐Over Study. Veterinary Dermatology. https://doi.org/10.1111/vde.70010
Vancouver
Leon R, Starr H, Banovic F. Evaluation of One‐Time Oral Oclacitinib Administration on Pruritic Behaviours After Intradermal Interleukin‐31‐Induced Pruritus Injections (“Reactive” Model) in Healthy Dogs: A Blinded, Randomised, Cross‐Over Study. Veterinary Dermatology. 2025. doi:10.1111/vde.70010
BibTeX
@article{Leon2025,
author = {Leon, Renato and Starr, Haley and Banovic, Frane},
title = {Evaluation of One‐Time Oral Oclacitinib Administration on Pruritic Behaviours After Intradermal Interleukin‐31‐Induced Pruritus Injections (“Reactive” Model) in Healthy Dogs: A Blinded, Randomised, Cross‐Over Study},
journal = {Veterinary Dermatology},
year = {2025},
doi = {10.1111/vde.70010}
}
EUVIMED